Can We Now Agree to Use the Same Definition to Measure Response According to CA-125?
Author:
- 15 October 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (20) , 4035-4036
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)JNCI: Journal of the National Cancer Institute, 2004
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]JNCI: Journal of the National Cancer Institute, 2000
- Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983